bluuebunny/crossref_metadata_2025_split huggingface dataset:
Long-term Progression and Risk Factors of Fundus Tessellation in the Beijing Eye Study
Authors: Yan Yan Ni , Wang Ya Xing , Yang Yan , Xu Liang , Xu Jie , Wang Qian , Yang Xuan , Yang Jing Yan , Zhou Wen Jia , Wei Wen Bin , Jonas Jost B. 
Published: July 2018

AbstractTo assess the progression of fundus tessellation, color fundus photographs of the participants of the longitudinal population-based Beijing Eye Study were examined. The study included 4439 subjects in 2001 and 2695 (66.4% of the surviving) individuals in 2011. Larger progression in macular fundus tessellation (mean: 0.24 ± 0.48 grades) was associated (multivariate analysis; correlation coefficient r: 0.53) with thinner subfoveal choroidal thickness in 2011 (P < 0.001; standardized regression coefficient beta: −0.37), older age (P < 0.001; beta: 0.22), higher level of education (P < 0.001; beta: 0.09), more myopic change in refractive error (P < 0.001; beta: −0.09) and lower cognitive function score (P = 0.02; beta: −0.05). Larger increase in peripapillary fundus tessellation (mean: 0.19 ± 0.26 grades) correlated with thinner peripapillary choroidal thickness in 2011 (P < 0.001; beta: −0.35), older age (P < 0.001; beta: 0.20), worse best corrected visual acuity (P = 0.001; beta: 0.07), more myopic change in refractive error (P < 0.001; beta: −0.07) and higher prevalence of ever smoking (P = 0.004; beta: 0.05). The increase in macular fundus tessellation, as a surrogate for thinning of the posterior choroid, was associated with lower cognitive function, after adjusting for choroidal thickness, age, educational level and change in refractive error. The findings point to the clinical value of the assessment of fundus tessellation and suggest potential associations between cognitive function and fundus tessellation/choroidal thickness.
The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation
Authors: Yamaguchi Masaru , Hirouchi Tokuhisa , Yokoyama Koki , Nishiyama Ayaka , Murakami Sho , Kashiwakura Ikuo 
Published: July 2018

AbstractFor the primary treatment of emergency exposure to high-dose radiation, such as in the event of a radiation accident, the top priority is the reconstitution and restoration of haematopoiesis. In most radiation accidents, drug therapy is chosen as the most suitable treatment; the chosen drug should already be approved domestically, stably supplied and regularly stockpiled. In the present study, a single administration of romiplostim (RP), an approved thrombopoietin receptor agonist, produced a 100% survival rate in C57BL/6 J mice exposed to a lethal dose (7 Gy) of137Cs γ-rays, and all irradiated mice survived for more than 30 days with both 3- and 5-day consecutive administrations. By day 30, the peripheral blood cells, bone marrow cells and haematopoietic progenitor cells of the RP-administered irradiated mice had all recovered to a level that was not significantly different from that in non-irradiated mice. In contrast to myelosuppression, which did not fully recover until day 30, the expression of several bone marrow cell surface antigens recovered sooner, and DNA repair concurrently increased in haematopoietic cells, speeding the resolution of double strand breaks and reducing the rates of apoptosis. These findings suggest that RP may be a clinic-ready countermeasure to treat victims of radiation accidents.
Treatment of Cutting Fluid Waste using Activated Carbon Fiber Supported Nanometer Iron as a Heterogeneous Fenton Catalyst
Authors: Su Chunjian , Cao Gaohua , Lou Shumei , Wang Rui , Yuan Fengru , Yang Longyun , Wang Qing 
Published: July 2018

AbstractAddressing the problem of high chemical oxygen demands (COD) of cutting fluid waste generated in the machining process, its complex composition, and the specific conditions required for the treatment process, a heterogeneous Fenton fibre catalyst (NZVI@ACF) made of nanometer-iron supported on activated carbon fiber using dip-molding was developed. NZVI was homogeneously loaded onto ACF surfaces to form NZVI@ACF, with a specific surface area (SBET) of 726.3642 m2/g. Using a multistage chemical pretreatment, the NZVI@ACF/H2O2 system was used to effectively treat cutting fluid waste. The results indicated that the rate of COD removal in the cutting fluid waste liquid pretreated with NZVI@ACF/H2O2 system was 99.8% when the reactions conditions were optimized to 20 nmol/L H2O2, 6 g/L NZVI@ACF, total reaction time of 120 min and pH 5. The treated waste solution passed China’s tertiary wastewater discharge standards. NZVI@ACF/H2O2 demonstrated an excellent catalytic performance compared to the traditional Fenton catalyst, increased the effective pH reaction range and had an adsorption effect on the waste liquid after the reaction.
Blocking CCL5-CXCL4 heteromerization preserves heart function after myocardial infarction by attenuating leukocyte recruitment and NETosis
Authors: Vajen Tanja , Koenen Rory R. , Werner Isabella , Staudt Mareike , Projahn Delia , Curaj Adelina , Sönmez Tolga Taha , Simsekyilmaz Sakine , Schumacher David , Möllmann Julia , Hackeng Tilman M. , Hundelshausen Philipp von , Weber Christian , Liehn Elisa A. 
Published: July 2018

AbstractMyocardial infarction (MI) is a major cause of death in Western countries and finding new strategies for its prevention and treatment is thus of high priority. In a previous study, we have demonstrated a pathophysiologic relevance for the heterophilic interaction of CCL5 and CXCL4 in the progression of atherosclerosis. A specifically designed compound (MKEY) to block this CCL5-CXCR4 interaction is investigated as a potential therapeutic in a model of myocardial ischemia/reperfusion (I/R) damage. 8 week-old male C57BL/6 mice were intravenously treated with MKEY or scrambled control (sMKEY) from 1 day before, until up to 7 days after I/R. By using echocardiography and intraventricular pressure measurements, MKEY treatment resulted in a significant decrease in infarction size and preserved heart function as compared to sMKEY-treated animals. Moreover, MKEY treatment significantly reduced the inflammatory reaction following I/R, as revealed by specific staining for neutrophils and monocyte/macrophages. Interestingly, MKEY treatment led to a significant reduction of citrullinated histone 3 in the infarcted tissue, showing that MKEY can prevent neutrophil extracellular trap formation in vivo. Disrupting chemokine heterodimers during myocardial I/R might have clinical benefits, preserving the therapeutic benefit of blocking specific chemokines, and in addition, reducing the inflammatory side effects maintaining normal immune defence.
Novel triadius-like N4 specie of iron nitride compounds under high pressure
Authors: Chen Yuanzheng , Cai Xinyong , Wang Hongyan , Wang Hongbo , Wang Hui 
Published: July 2018

AbstractVarious nitrogen species in nitrides are fascinating since they often appear with these nitride as superconductors, hard materials, and high-energy density. As a typical complex, though iron nitride has been intensively studied, nitrogen species in the iron–nitrogen (Fe-N) compounds only have been confined to single atom (N) or molecule nitrogen (N2). Using a structure search method based on the CALYPSO methodology, unexpectedly, we here revealed two new stable high pressure (HP) states at 1:2 and 1:4 compositions with striking nitrogen species. The results show that the proposed FeN2 stabilizes by a break up of molecule N2 into a novel planar N4 unit (P63/mcm, >228 GPa) while FeN4 stabilizes by a infinite 1D linear nitrogen chains N∞ (P-1, >50 GPa; Cmmm, >250 GPa). In the intriguing N4 specie of P63/mcm-FeN2, we find that it possesses three equal N = N covalent bonds and forms a perfect triadius-like configuration being never reported before. This uniqueness gives rise to a set of remarkable properties for the crystal phase: it is identified to have a good mechanical property and a potential for phonon-mediated superconductivity with a Tc of 4–8 K. This discovery puts the Fe-N system into a new class of desirable materials combining advanced mechanical properties and superconductivity.
Der akute Gichtanfall in der zentralen Notaufnahme
Authors: Engel Bettina , Schacher Sylvia , Weckbecker Klaus , Stausberg Annika , Gräff Ingo 
Published: July 2018

Zusammenfassung
Hintergrund Die akute Arthritis urica ist eine i. d. R. durch Allgemeinmediziner behandelte Erkrankung. Die Prävalenz beträgt etwa 1,4% und kommt im höheren Lebensalter häufiger vor (bis zu 4,2% bei Männern > 75 Jahre). Bisher wurde in Deutschland noch nicht evaluiert, wann und bei welchen Patienten mit akuter Arthritis urica eine Behandlung in einer zentralen Notaufnahme stattfindet und ob diese leitliniengerecht stattfindet. Diese Studie evaluiert daher Charakteristika und Behandlungspfade von Notfallpatienten mit akutem Gichtanfall in einer zentralen Notaufnahme in Deutschland.
Methoden Retrospektive Analyse der Patienten mit den ICD-Codes M10.xx von 05/2013 bis 04/2016 in der zentralen Notaufnahme eines universitären Krankenhauses.
Ergebnisse 65 Patienten stellten sich im o. g. Zeitraum aufgrund eines akuten Gichtanfalles vor. 42 Patienten (65%) stellten sich außerhalb der Praxisöffnungszeiten vor. Anamnestisch gaben 31 (47,69%) Patienten eine bekannte Hyperurikämie an, davon 22 (70,96%) mit Gichtanfall in der Vorgeschichte. Es stellten sich 48 (73%) Patienten mit einer Monarthritis vor, davon 40 mit Podagra (68%). Diagnostisch wurde bei 57 (86%) eine Blutentnahme durchgeführt. Eine Röntgenaufnahme des betroffenen Gelenks erfolgte bei 31 (48%) Patienten, 67% davon ohne Indikation. Eine Gelenkpunktion mit Kristallnachweis erfolgte bei 4 Patienten. Zwölf Patienten (18%) wurden fachspezifisch stationär aufgenommen zur chirurgischen Revision und/oder antibiotischen Behandlung. 51 Patienten (78%) erhielten primär nicht steroidale Antirheumatika (NSAR), 7 in Kombination mit Glukokortikoiden und 4 Kolchizin. Vor der NSAR-Gabe war bei 17 Patienten die Nierenfunktion nicht bekannt oder eingeschränkt. Elf Patienten (16%) erhielten weder NSAR, Kortison noch Kolchizin. Zehn Patienten (15%) erhielten im akuten Gichtanfall eine harnsäuresenkende Therapie bzw. deren Dosierung wurde verändert. Zusätzlich erhielten 63% der Patienten eine Empfehlung zur Durchführung nicht medikamentöser Maßnahmen.
Schlussfolgerungen Wir konnten zeigen, dass die pharmakologische Behandlung der Patienten mit einem akuten Gichtanfall größtenteils leitliniengerecht erfolgt. Jedoch sollte die Vigilanz bez. der Nierenfunktion vor NSAR-Gabe geschärft werden. Überwiegend stellten sich die Patienten außerhalb der Praxisöffnungszeiten vor, was die primär ambulante Versorgung der Gichtpatienten bestätigt. Die aktuellen Leitlinien empfehlen die Diagnose der unkomplizierten Gicht anhand rein klinischer Diagnosekriterien. Dementgegen fand sich eine Überversorgung mit diagnostischen Maßnahmen in der zentralen Notaufnahme. Abschließend zeigte unsere Untersuchung, dass diese klinischen Diagnosekriterien besser im klinischen Alltag implementiert werden sollten, um unnötige Röntgen- und Laboruntersuchungen zu vermeiden.
Welche Behandlung wirkt beim Hörsturz am besten?
Authors: Schartinger Volker 
Published: July 2018

Ashtiani MK at al. Efficacy of systemic and intratympanic corticosteroid combination therapy versus intratympanic or systemic therapy in patients with idiopathic
sudden sensorineural hearing loss: a randomized controlled trial. Eur Arch Otorhinolaryngol 2018; 275: 89–7
Iranische HNO-Ärzte verglichen die Heilungsraten einer Behandlung des idiopathischen Hörsturzes mit oralen und intratympanalen Kortikosteroidgaben in Mono-
und Kombinationstherapien.
Ergebnisse der langjährigen Substitutionsbehandlung Opiatabhängiger – die SubsCare-Studie
Authors: Zippel-Schultz Bettina , Specka Michael , Stöver Heino , Nowak Manfred , Cimander Konrad , Maryschok Markus , Poehlke Thomas , Helms Thomas , Scherbaum Norbert 
Published: July 2018

Zusammenfassung
Ziel Erhebung des gesundheitlichen und sozialen Zustands von mehr als 5 Jahre opiatsubstituierten Patienten.
Methodik 130 Patienten aus 12 Praxen wurden über 2 Jahre beobachtet und mittels standardisierter Fragebögen befragt.
Ergebnisse Die Haltequote über 2 Jahre betrug 82,3%; nur 4 Patienten beendeten die Behandlung regulär. 25% waren durchgehend frei von Alkohol und Drogen. 25% waren kontinuierlich sozialversicherungspflichtig beschäftigt. Die Mehrheit wies Komorbiditäten sowie Defizite in der sozialen Teilhabe auf.
Schlussfolgerung Viele Patienten erreichten Stabilität im Hinblick auf Abstinenz von Suchtmitteln und soziale Teilhabe. Jedoch zeigt eine große Patientengruppe körperliche und psychische Begleiterkrankungen sowie noch erhebliche Defizite in der Teilhabe. Vor allem für diese Patienten erscheint eine zeitliche Limitierung der Substitutionsbehandlung nicht realitätsgerecht.
Warum die Zertifizierung von Darmkrebszentren die chirurgische Ergebnisqualität nicht verbessert
Authors: Vogel Peter Alexander 
Published: July 2018

Zusammenfassung
Hintergrund Die Zertifizierung von Darmkrebszentren führt zu einer interdisziplinären Behandlung nach Leitlinien. Die Ergebnisse der zertifizierten Zentren werden jährlich publiziert. Die Jahresvergleiche zeigen, dass sich die chirurgische Ergebnisqualität gemessen anhand der Indikatoren Anastomoseninsuffizienz, Wundinfekt und Revisionsoperationen zwischen 2009 und 2015 nicht verbessert hat.
Patienten und Methoden In einer nach London-Protokoll strukturierten Morbiditäts- und Mortalitätskonferenz (M+M-Konferenz) wurden Patienten mit Anastomoseninsuffizienz (AI) nach kolorektaler Resektion wegen Adenokarzinom analysiert. Die Ergebnisse wurden mit den im Erhebungsbogen der Deutschen Krebsgesellschaft (DKG) für die Zertifizierung von Zentren genannten Prozess- und Strukturparametern verglichen.
Ergebnisse Von 2015 bis 2017 wurden 387 kolorektale Resektionen durchgeführt. 158 Resektionen erfolgten unter der Diagnose eines kolorektalen Karzinoms. Bei 13/149 Resektionen mit Anastomose musste eine Insuffizienz diagnostiziert werden (8,7%). Alle Patienten mit einer AI wurden in einer nach London-Protokoll strukturierten M+M-Konferenz analysiert. Bei 10/13 Patienten wurden Auffälligkeiten im Bereich von Struktur- oder Prozessqualität benannt. Dies betraf hinsichtlich der Prozessqualität die Handhabung von Standards (n = 6/10), die Kommunikation (n = 3/10) und das Fehlen benötigter Untersuchungsergebnisse (n = 1/10). Hinsichtlich der Strukturqualität standen nicht ausreichende materielle Ressourcen im Vordergrund (3/10). Nur 1/13 Auffälligkeiten wird in den im Erhebungsbogen (EB) genannten Struktur- oder Prozessparametern abgebildet.
Schlussfolgerung Voraussetzung dafür, dass Prozesse und Strukturen die Ergebnisqualität verbessern, ist, dass sie relevanten Einfluss auf die Ergebnisqualität haben. Unsere Untersuchung ergab, dass nur 1/13 der in der nach London-Protokoll strukturierten M+M-Konferenz gefundenen Auffälligkeiten im EB abgefragt wird. Um Prozess- und Strukturparameter, die in der konkreten klinischen Praxis an der Entstehung und am Verlauf von Komplikationen (hier AI) beteiligt sind, besser abzubilden, sollten Ergänzungen im EB der DKG diskutiert werden.
Homzygous Protein S Deficiency due to a One Base Pair Deletion that Leads to a Stop Codon in Exon III of the Protein S Gene
Authors: Gómez E , Ledford M R , Pegelow C H , Reitsma P H , Bertina R M 
Published: July 2018

SummaryHomozygous protein S (PS) deficiency is a very rare disorder that causes purpura fulminans in affected newborns. This report describes the molecular genetic abnormality of a severe PS deficient child who developed purpura fulminans shortly after birth. The mutation was identified as a deletion of one adenine in codon 43 of exon III of the PROS 1 gene. This mutation results in a frameshift and a novel stop codon at position 45. The proband was apparently homozygous and his mother heterozygous for this mutation. The proband’s father was not available for study.The single base pair deletion predicts a truncated translation product, where Lys 43 and Tyr 44 have been replaced by Asn 43 and Thr 44. This putative protein (predicted mw of 5.696 daltons) contains only the gammacarboxyglutamic acid (Gla) domain and the aromatic stack.
Assessment of the Validity of the INR System for Patients with Liver Impairment
Authors: Kovacs M J , Wong A , MacKinnon K , Weir K , Keeney M , Boyle E , Cruickshank M 
Published: July 2018

SummaryThe INR system was developed to standardize PT reporting in patients on oral anticoagulants. We prospectively collected blood samples from 29 patients with liver impairment (INR 1.5-3.5). Control patients were on warfarin (n = 31). PT’s were measured on an ACL-300 with three thromboplastin reagents. INR’s were calculated using instrument specific ISI’s. Other tests performed were FDP’s, fibrinogen, aPTT, factors II, V, VII and X. The INR’s for each patient in the study population using the three thromboplastin reagents were significantly different (p = 0.0001). Those for the control population were not (p = 0.0658). Fibrinogen, factors V, II and X were different at the 5% level of significance between the populations. FDP’s were detected in 17 study subjects. The INR system is not valid for comparison of patients with liver impairment because different reagents do not give the same INR for the same sample. It is, however, no less valid than the use of PT with different thromboplastin reagents. Further study is recommended.
Non-Fasting Factor VII Coagulant Activity (FVII:C) Increased by High-Fat Diet
Authors: Bladbjerg E M , Marckmann P , Sandström B , Jespersen J 
Published: July 2018

SummaryPreliminary observations have suggested that non-fasting factor VII coagulant activity (FVII:C) may be related to the dietary fat content. To confirm this, we performed a randomised cross-over study. Seventeen young volunteers were served 2 controlled isoenergetic diets differing in fat content (20% or 50% of energy). The 2 diets were served on 2 consecutive days. Blood samples were collected at 8.00 h, 16.30 h and 19.30 h, and analysed for triglycerides, FVII coagulant activity using human (FVII:C) or bovine thromboplastin (FVII:Bt), and FVII amidolytic activity (FVIPAm). The ratio FVII:Bt/FVII:Am (a measure of FVII activation) increased from fasting levels on both diets, but most markedly on the high-fat diet. In contrast, FVII: Am (a measure of FVII protein) tended to decrease from fasting levels on both diets. FVII:C rose from fasting levels on the high-fat diet, but not on the low-fat diet. The findings suggest that high-fat diets increase non-fasting FVII:C, and consequently may be associated with increased risk of thrombosis.
Molecular Cloning and Expression of Rabbit Heparin Cofactor II: A Plasma Thrombin Inhibitor Highly Conserved between Species
Authors: Sheffield William P , Schuyler Philip D , Blajchman Morris A 
Published: July 2018

SummaryHeparin cofactor II (HCII), a circulating plasma protein that inhibits thrombin, is a member of the serine proteinase (serpin) family of proteins. The extent to which HCII structure is conserved actross species lines was investigated, by obtaining cDNA clones encoding rabbit HCII. Overlapping clones corresponding to rabbit HCII were obtained by the combined use of hybridization screening of a rabbit liver cDNA library, and by rapid amplification of cDNA ends (RACE). The consensus sequence obtained spans 2178 nucleotides, and is comprised of a 5' untranslated region of 77 nucleotides, an open reading frame of 1440 nucleotides, and 3' untranslated region of 661 nucleotides that concludes with a poly A tract. The open reading frame is subdivided into a secretory signal sequence of 19 amino acids, and a mature protein of 461 amino acids. Within the region comprising the mature protein, 87% of the amino acid residues are identical to those seen in human HCII. Expression of an appropriately modified form of the rabbit HCII clone in an in vitro reticulocyte expression system yielded two major polypeptides, of 60 and 56 kD respectively, both of which were able to form SDS-stable complexes with human α-thrombin, in a reaction accelerated by dermatan sulphate. The remarkable degree of homology observed between rabbit HCII and its human conterpart, indicating a high degree of conservation of structure through evolution, suggests an important function of HCII in hemostatis.
In Vivo Effect of Suloctidil as an Antiplatelet Agent
Authors: Stelzer Marcia R , Burns Thomas S , Saunders Robert N 
Published: July 2018

SummaryThe relationship between the effects of suloctidil in vivo as an antiplatelet agent and in vitro as a modifier of platelet serotonin (5-HT) parameters was investigated. Suloctidil was found to be effective in reducing platelet aggregates formation in the retired breeder rat as determined using the platelet aggregate ratio method (PAR) with an ED50 of 16.1 mg/kg 24 hours post administration. In contrast to the hypothesis that 5-HT depletion is involved in the anti-aggregatory mechanism of suloctidil, no correlation was found between platelet 5- HT content and this antiplatelet activity. Reduction of platelet 5-HT content required multiple injections of high doses (100 mg/kg/day) of suloctidil. Suloctidil administration for 8 days at 100 mg/kg/day, which lowered platelet 5-HT content by 50%, resulted in no permanent effect on ex vivo platelet 5-HT uptake or thrombin-induced release, nor alteration in the plasma 5-HT level. However, these platelets exhibited a short-lived, significant increase in percent leakage of 5-HT after 30 minutes of incubation. Therefore, suloctidil treatment at high doses may with time result in platelet 5-HT depletion, however this effect is probably not related to the primary anti-aggregatory activity of the drug.
Effect of Factor XII Deficiency on Pregnancy and Parturition
Authors: Saidi Parvin , Siegelman Martin , Mitchel Valerie B 
Published: July 2018

SummaryThe clotting parameter of a primigravida with factor XII deficiency was studied during her third trimester of pregnancy, labor and post-partum; and compared with those of her newborn male infant. Sharp increases in factors VII, VIII, IX, X and moderate increases in factors II and XI were documented during pregnancy and at labor. All factors had returned to normal or near normal levels 24 hours after delivery. Factor XII remained at 0.0 level throughout. In the infant the clotting factor levels reflected depression of vitamins Independent factors II, IX and X and a factor XII level of 40.0%. No undue bleeding was noted in the mother at delivery or placental separation, and no bleeding manifestation was apparent in the infant. These findings suggest that factor XII does not play a major role in triggering or modulating the course of normal labor, nor is its absence necessarily associated with bleeding complications during parturition or placental separation.